Reporting the counterparty's growth as its own: management explains the company's coming year by narrating what its cust
The model's full reasoning — Q1 2018 call → NOThe question asks whether management explains the company's direction by narrating what its counterparties are doing and scaling. Let me analyze the transcript carefully. The management discusses: - Strong order growth, but attributes it to customers placing orders earlier due to extended lead times and chassis availability concerns - They discuss their own capacity additions (adding shifts, hiring 50 people at Vactor, adding laser cutting tools) - They discuss their own pricing actions and steel procurement - They discuss their own new products (Vactor rapid deployment boom, Allegiant lightbar) - They discuss their own ETI program for productivity improvements The order acceleration is attributed to customers' procurement strategies (placing orders earlier), not to customers' own expansion, ramp, or build-out. The management doesn't describe specific counterparties' growth trajectories, their own ramps, launches, or build-outs. Instead, they describe their own capacity additions and their own actions. The discussion of chassis availability is about supply constraints, not about counterparties' expansion. The discussion of steel prices is about commodity costs, not counterparty trajectories. The management's forward account is about their own actions: adding capacity, price increases, productivity programs, new products. They don't narrate what specific customers or partners are building or scaling. The answer is NO.
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| EMKR | EMCORE Corporation | Q4 2023 | 2023-12-12 | C+ |
| MBLY | Mobileye Global Inc. | Q2 2023 | 2023-07-28 | B+ |
| PI | Impinj, Inc. | Q4 2022 | 2023-02-08 | B+ |
| FAT | FAT Brands Inc. | Q4 2021 | 2022-03-21 | F |
| OOMA | Ooma, Inc. | Q3 2022 | 2021-12-02 | B+ |
| ILMN | Illumina, Inc. | Q1 2018 | 2018-04-24 | A |
| PLAB | Photronics, Inc. | Q2 2017 | 2017-05-17 | C+ |
| IONS | Ionis Pharmaceuticals, Inc. | Q1 2017 | 2017-05-09 | C |
| FNV | Franco-Nevada Corporation | Q3 2016 | 2016-11-08 | B+ |
| HXL | Hexcel Corporation | Q4 2015 | 2016-01-22 | B+ |
OOMA · Q3 2022 → YESThe question is about whether management narrates what its counterparties are doing and scaling, presenting the company's future volume as a consequence of those parties' trajectories.
MBLY · Q2 2023 → YESThe question is about whether management narrates what its counterparties are doing and scaling, presenting the company's volume as a consequence of those parties' trajectories.
ILMN · Q1 2018 → YESThe question is about whether management narrates what its counterparties are doing and scaling, presenting the company's future as a consequence of those parties' trajectories.